Credit Suisse Group AG has enlarged the banking syndicate underwriting the rights issue and announces the reference price, the purchase price and maximum number of new shares to be issued to and to be purchased by a number of qualified investors without the pre-emptive subscription rights of existing shareholders as well as the expected terms of the rights issue.
The arm is part of the I-SPY 2 Endocrine Optimization Platform (EOP), which is focused on patients with clinically high-risk (stage 2/3) estrogen receptor-positive (ER+)/HER2- breast cancer, but the molecularly